PeptideNerds

Retatrutide Benefits

Clinical TrialsGLP-1 / Weight Loss
FM

Reviewed by Fat Man in the Arena · Updated March 2026

Not medical advice. This content is for educational purposes only. Consult a healthcare provider before starting any peptide protocol. Full disclaimer.

How Retatrutide works

Retatrutide activates three receptors simultaneously: GIP, GLP-1, and glucagon. The addition of glucagon receptor activation increases energy expenditure and fat oxidation beyond what dual agonists achieve, creating a three-pronged approach to weight loss.

Reported benefits

Based on available research data, Retatrutide has been associated with the following benefits:

  • Up to 24.2% weight loss in Phase 2 trials
  • Potentially the most effective weight loss compound studied
  • Triple receptor action for enhanced fat burning
  • Significant reduction in liver fat
  • Improved metabolic markers across the board

Supporting research

Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2)

New England Journal of Medicine, 2023 · PMID: 37351564

At the 12 mg dose, participants lost 24.2% of body weight over 48 weeks. This is the largest weight loss ever reported for any anti-obesity medication in clinical trials.

Important context

Benefits reported in clinical trials represent average outcomes across study populations. Individual results vary based on genetics, dosage, duration, and lifestyle factors.

Weekly peptide research updates

New studies, GLP-1 news, protocol insights, and weight loss data — delivered every week. Free. No spam.